Drug Profile
Research programme: antifungal therapeutics - Selmod
Alternative Names: AB 284Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Selmod
- Class Anti-infectives; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Mycoses in Switzerland
- 20 Jul 2016 Early research in Mycoses in Switzerland (unspecified route) before July 2016
- 10 Feb 2016 AB 284 has patent protection (Selmod Presentation, February 2016)